Need professional-grade analysis? Visit stockanalysis.com
$1.47B
N/A
N/A
N/A
Price Chart
Risk-Adjusted Performance
Nuvation Bio Inc (NUVB) Price Performance
Nuvation Bio Inc (NUVB) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $4.22, down 1.40% from the previous close.
Over the past year, NUVB has traded between a low of $1.66 and a high of $9.54. The stock has gained 117.5% over this period. It is currently 55.8% below its 52-week high.
Nuvation Bio Inc has a market capitalization of $1.47B.
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Company Info
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- $62.90M
- EBITDA
- $-211,324,992
- Profit Margin
- -7213.76%
- EPS (TTM)
- -0.60
- Book Value
- 0.88
Technical Indicators
- 52 Week High
- $9.75
- 52 Week Low
- $1.54
- 50 Day MA
- $6.02
- 200 Day MA
- $4.52
- Beta
- 1.51
Valuation
- Trailing P/E
- N/A
- Forward P/E
- -32.46
- Price/Sales
- 23.32
- Price/Book
- 4.78
- Enterprise Value
- $1.00B